| Italia | Turchia | Austria | |
| Trapianto di midollo osseo allogenico da donatore non correlato | da $150,000 | da $80,000 | da $180,000 |
| Trapianto di midollo osseo allogenico da donatore consanguineo | da $120,000 | da $65,000 | da $150,000 |
| Trapianto di midollo osseo | da $95,000 | da $36,000 | da $140,000 |
| Terapia con cellule CAR-T | da $350,000 | da $150,000 | da $350,000 |
| Terapia biologica | da $18,000 | da $5,500 | da $20,000 |
Bookimed non aggiunge costi extra ai prezzi dei trattamenti di Ematologia Oncologia. Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica al tuo arrivo nel paese.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali nei trattamenti di Ematologia Oncologia e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di trattamento di procedure di Ematologia Oncologia.
Responsabile del più grande programma di trapianto di midollo osseo d'Italia – Il Dr. Peccatori supervisiona oltre 90 trapianti allogenici ogni anno al San Raffaele.
Fondatore della Fondazione Italiana Linfomi – il Prof. Ferreri guida ricerche e trattamenti all'avanguardia presso l'Unità Linfomi del San Raffaele.
Oltre 900 trapianti di midollo osseo eseguiti – Il Professor Fabio Ciceri dirige l'Unità di Ematologia e Trapianto di Midollo Osseo presso l'Ospedale San Raffaele.
Il medico dirige l'Unità di Immunoematologia Pediatrica presso l'Ospedale di Ricerca San Raffaele a Milano e svolge il ruolo di Professore Universitario. Specializzandosi in ematologia, immunologia e pediatria, il medico si concentra sulle immunodeficienze primarie e sulla terapia genica, in particolare per ADA-SCID e la Sindrome di Wiskott-Aldrich.<\/p>
Con una carriera che si estende per oltre due decenni, il medico ha ricoperto posizioni chiave nella ricerca clinica pediatrica e nella terapia genica. Il medico è autore di oltre 180 pubblicazioni e collabora a progetti di ricerca con varie organizzazioni prestigiose.<\/p>
Hematology-oncology care in Italy is safe and highly regulated, meeting strict European Union medical standards. Specialized centers like San Raffaele utilize advanced technologies, including the world first stem cell therapies. Facilities provide multidisciplinary care for complex conditions like leukemia and lymphoma with high survival rates.
Bookimed Expert Insight: Italian medical hubs like Milan offer a unique safety advantage for rare diseases. San Raffaele serves 300,000 patients annually and develops ad hoc methods for genetic disorders. Patients seeking these specialized treatments should look for centers with IRCCS status. This designation confirms the hospital performs high-level research alongside clinical practice.
Patient Consensus: Patients note that care in northern Italy is efficient and matches top European standards. Many emphasize that having a medical visa and private insurance helps avoid waiting lists.
Hematology oncology specialists in Italy must hold a medical degree and specific specializations in hematology or oncology. Top experts often participate in international research. Many lead trials in advanced therapies. Institutional accreditation like IRCCS confirms their involvement in high-level clinical research.
Bookimed Expert Insight: Our data shows that top Italian hematologists are often principal investigators in global gene therapy trials. At San Raffaele, surgeons performed the world's first stem cell therapy for ADA-SCID. This level of expertise attracts over 300,000 patients annually to these specific Milanese hubs.
Patient Consensus: Patients recommend checking if a doctor has international fellowship experience. They also note that department heads often delegate daily care to younger teams with trial access.
Hematology-oncology procedures in Italy carry risks like myelotoxicity, infections, and procedural pain from biopsies. Advanced treatments like allogeneic bone marrow transplantation may lead to graft-versus-host disease. Highly specialized centers like San Raffaele Hospital emphasize rigorous protocols to manage these systemic toxicities and improve recovery.
Bookimed Expert Insight: Italian centers like San Raffaele Hospital often lead in safety by integrating research directly into clinical care. For instance, being the first to perform ADA-SCID stem cell therapy suggests a high level of technical precision. Patients should note that units performing 90+ allogeneic transplants annually, such as Dr. Jacopo Peccatori's team, typically have more refined protocols for managing complex post-transplant complications.
Patient Consensus: Patients note that while the anti-emetic medications used in Italy are very effective, the fatigue and nerve tingling can last for months. Many emphasize the importance of tracking daily symptoms to ensure prompt adjustments to treatment cycles.
Patients typically require 4 to 12 weeks in Italy for hematology oncology treatments like bone marrow transplants. Stays include 2 to 3 weeks of inpatient isolation and follow-up monitoring. Chemotherapy cycles often last 1 to 2 weeks per session. Full courses may span 3 months.
Bookimed Expert Insight: Coordination of lodging is vital at centers like San Raffaele in Milan. This hospital handles over 52,000 operations annually and offers specialized gene therapy. Their all-inclusive BMT packages often bundle hotel stays. Choosing these helps patients manage the long recovery window without separate logistics.
Patient Consensus: Patients note it is important to book flexible housing near the clinic. Staying for several months is common, so having family along helps manage the isolation during intensive treatment phases.
Italian oncology centers provide language support through dedicated international patient offices and multilingual medical staff. Specialized facilities like San Raffaele in Milan employ coordinators to bridge communication gaps. Many lead hematologists, including Dr. Fabio Ciceri and Dr. Alessandro Aiuti, conduct international research and often speak fluent English.
Bookimed Expert Insight: Northern Italian hubs like Milan show a clear advantage in language accessibility. Research-heavy centers like San Raffaele attract international experts, which naturally increases the density of English-speaking staff. Patients targeting complex treatments like bone marrow transplants often find better logistical support in these high-volume academic institutions.
Patient Consensus: Patients note that while top doctors often speak English, administrative staff and nurses may not. It is helpful to request an English-speaking coordinator weeks in advance to avoid communication hurdles during daily care.
Italian medical centers generally require international patients to provide upfront self-payment for hematology oncology treatments. Facilities like San Raffaele in Milan typically do not bill foreign insurance providers directly. Patients must pay out-of-pocket and then submit detailed invoices to their insurers for reimbursement later.
Bookimed Expert Insight: High-volume research hospitals like San Raffaele, which serves 300,000 patients annually, operate more like academic institutions than commercial clinics. Because they manage complex cases like the world's first stem cell therapy for ADA-SCID, their billing departments prioritize clinical intake over insurance negotiations. Most successful international patients secure treatment faster by paying the hospital invoice first and handling the insurance claim as a secondary step from home.
Patient Consensus: Patients note that you should budget for the total cost of oncology care upfront. They often share that while the medical care is exceptional, getting a non-EU insurance company to pay the clinic directly is nearly impossible.
Milan, Rome, and Bologna are Italy's leading hubs for hematology-oncology. Milan is the primary destination for international patients. It hosts centers like San Raffaele, which pioneered the world's first stem cell therapy for ADA-SCID. These cities offer advanced gene therapies and complex bone marrow transplants.
Bookimed Expert Insight: Milan's dominance in hematology-oncology stems from its high-volume research hospitals like San Raffaele. This facility treats 300,000 patients annually and maintains a massive 430-bed capacity. For medical tourists, this volume translates to faster access to experimental cell therapies and highly specialized doctors who handle the most complex leukemia cases in Europe.
Patient Consensus: Patients note that Milan's private centers are the best choice for avoiding bureaucracy and securing English-speaking support. One patient highlighted that Italian research trials offer a high standard of care for myeloma at more accessible rates compared to other European hubs.